Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
✕

News

September 29, 2023
September 29, 2023

Novel DNA vaccine Elenagen demonstrates promising clinical results

Novel DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer
Do you like it?
0 Read more
December 4, 2023
December 4, 2023

DNA therapy effective against chemo-resistant ovarian cancer

Do you like it?
0 Read more
February 22, 2024
February 22, 2024

Elenagen, a novel DNA immunotherapy for ovarian cancer, found to delay disease progression

Progression-free survival of patients treated with chemo+ELENAGEN or chemo only.
Do you like it?
0 Read more
February 29, 2024
February 29, 2024

Study undermines mechanism-based discovery, says CureLab

Do you like it?
0 Read more
Load more
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • IN THE NEWS
  • NEWS RELEASE
  • PRESS RELEASES
  • All
  • All
  • admin
September 29, 2023
September 29, 2023

Novel DNA vaccine Elenagen demonstrates promising clinical results

Novel DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer
Do you like it?
0 Read more
December 4, 2023
December 4, 2023

DNA therapy effective against chemo-resistant ovarian cancer

Do you like it?
0 Read more
February 22, 2024
February 22, 2024

Elenagen, a novel DNA immunotherapy for ovarian cancer, found to delay disease progression

Progression-free survival of patients treated with chemo+ELENAGEN or chemo only.
Do you like it?
0 Read more
February 29, 2024
February 29, 2024

Study undermines mechanism-based discovery, says CureLab

Do you like it?
0 Read more
Load more

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

© 2026 CureLab Oncology.